{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-045056","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2023-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.152461+00:00","generated_at":"2026-06-11T02:27:32.177482+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Erasca doses first patient in Phase 1b SEACRAFT-1 trial of naporafenib plus trametinib for RAS Q61X tumors","bullets":["SEACRAFT-1 evaluates pan-RAF inhibitor naporafenib + MEK inhibitor trametinib in RAS Q61X solid tumors; addressable patient population >150k in US/Europe.","Signal-seeking efficacy data expected between Q2 and Q4 2024.","Pivotal Phase 3 SEACRAFT-2 trial for NRAS-mutant melanoma on track to start H1 2024.","Naporafenib licensed from Novartis; Erasca has not conducted prior clinical trials of the drug."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-045056","json":"https://secwatch.observer/filing/0000950170-23-045056.json","markdown":"https://secwatch.observer/filing/0000950170-23-045056.md","text":"https://secwatch.observer/filing/0000950170-23-045056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023045056/0000950170-23-045056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023045056/eras-20230829.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T02:27:32.177482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}